Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS Trial* - Prasse, A; Maher, TM; Distler, O; Azuma, A; Highland, KB; Kuwana, M; Mayes, MD; Wachtlin, D; Alves, M; Gahlemann, M; Stowasser, S; Raghu, G (Pneumologie, 2020)